Reach Us +1-218-451-2974


Multi Target Directed Ligand: An Approach To Treat Alzheimer's Disease | 12551
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2275

Journal of Alzheimers Disease & Parkinsonism received 2275 citations as per Google Scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Multi target directed ligand: An approach to treat Alzheimer's disease

International Conference on Psychology, Autism and Alzheimers Disease

Priti Jain

Accepted Abstracts: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460.S1.004

Alzheimer?s disease (AD) is a complex neuro-degenerative disorder with a multifaceted pathogenesis. It is believed to affect around 107 million population worldwide by 2050 and is fourth most common cause of death in elderly population. Present paradigm of "one compound, one target" has failed to stop or delay the progression of disease because of the different targets involved in AD like amyloid precursor protein(APP), ?-secretase-1(BACE-1), glycogen synthase kinase3?, tau protein, histone deacetylase etc. This therefore supports the application of multi-target-directed ligand approach in the treatment of AD. The strategy involves designing the hybrids by linking structurally active moieties interacting with different targets. Each pharmacophore of these new drugs should retain the ability to interact with its specific site(s) on the target and consequently, produce specific pharmacological responses. This combination therapy is being used to treat various other disorders such as AIDS, atherosclerosis, cancer and depression. The approach could be a break-through for the development of new drugs capable of addressing the biological complexity of this disorder.
Priti Jain is pursuing Ph.D. in the field of Alzheimer's disease from BITS, Pilani, India. She is involved with the group since last 4 years. Before joining Ph.D., she had worked with Glenmark Research Centre for around 3 years (an esteemed Indian pharmaceutical company). She has published 3 papers related to QSAR studies and also on Alzheimer's disease. She is trying to do computational studies of novel BACE-1 inhibitors and synthesize the same molecules.